Flotek Industries is executing a high-growth pivot from cyclical chemistry to recurring data and mobile-power infrastructure, but ProFrac concentration and liquidity risks temper the upside.
Overview
Flotek Industries (FTK) is transitioning from a cyclical oilfield-chemistry supplier into a technology-enabled industrial infrastructure company spanning customized chemistry, optical analytics, recurring software, and mobile power. ECT remains the larger segment, but DA is driving mix improvement through PWRtek leases, XSPCT analyzers, VeraCAL flare monitoring, and Viper-connected subscriptions. Q2 2026 revenue increased 70% year over year to $99.367 million, adjusted EBITDA rose 109% to $16.788 million, and diluted EPS reached $0.26 versus $0.05 in Q2 2025. Management raised FY2026 revenue guidance to $340.0–$350.0 million and adjusted EBITDA guidance to $47.0–$51.0 million, excluding the potential impact of the 10-year, $400 million PREPA contract. **The key catalyst is converting PREPA deployment and analyzer expansion into durable recurring revenue.** DA generated 51% of consolidated gross profit in Q2 2026 despite representing $19.182 million of quarterly revenue, reflecting its approximately 75% gross margin versus roughly 20% for chemistry. The stock trades at a premium 37.43x trailing P/E versus a 21.54x Materials-sector average, but that premium reflects the business-mix transformation. The report’s probability-weighted five-year target is $53.21 versus a $35.68 reference price.